CINGULATE

Serial Number 88514366
Registration 6397240
700

Registration Progress

Application Filed
Jul 15, 2019
Under Examination
Apr 21, 2020
Approved for Publication
Feb 25, 2020
Published for Opposition
Feb 25, 2020
Registered
Jun 22, 2021

Basic Information

Serial Number
88514366
Registration Number
6397240
Filing Date
July 15, 2019
Registration Date
June 22, 2021
Published for Opposition
February 25, 2020
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
Jun 22, 2021
Registration
Registered
Classes
042

Rights Holder

Cingulate Therapeutics LLC

16
Address
1901 W 47th Place, Suite 310
Kansas City, KS 66205

Ownership History

Cingulate Therapeutics LLC

Original Applicant
16
Kansas City, KS

Cingulate Therapeutics LLC

Owner at Publication
16
Kansas City, KS

Cingulate Therapeutics LLC

Original Registrant
16
Kansas City, KS

Legal Representation

Attorney
Susan Neuberger Weller

USPTO Deadlines

Next Deadline
714 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-06-22)
Due Date
June 22, 2027
Grace Period Ends
December 22, 2027
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

33 events
Date Code Type Description
Jul 20, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 20, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 20, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 22, 2021 R.PR A REGISTERED-PRINCIPAL REGISTER
May 15, 2021 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 14, 2021 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Apr 26, 2021 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Apr 21, 2021 EISU I TEAS STATEMENT OF USE RECEIVED
Apr 21, 2021 IUAF S USE AMENDMENT FILED
Mar 25, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 24, 2021 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 24, 2021 EX1G S SOU EXTENSION 1 GRANTED
Jan 23, 2021 NREV E NOTICE OF REVIVAL - E-MAILED
Jan 22, 2021 PROA I TEAS PETITION TO REVIVE RECEIVED
Jan 22, 2021 PETG O PETITION TO REVIVE-GRANTED
Jan 22, 2021 TPEX I SOU EXTENSION RECEIVED WITH TEAS PETITION
Nov 23, 2020 ABN6 S ABANDONMENT - NO USE STATEMENT FILED
Nov 23, 2020 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 21, 2020 EXT1 S SOU EXTENSION 1 FILED
Apr 21, 2020 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 25, 2020 PUBO A PUBLISHED FOR OPPOSITION
Feb 25, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 5, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 23, 2020 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 16, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 15, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 15, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 11, 2019 CNRT R NON-FINAL ACTION WRITTEN
Oct 11, 2019 GNRT F NON-FINAL ACTION E-MAILED
Oct 11, 2019 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 30, 2019 DOCK D ASSIGNED TO EXAMINER
Jul 19, 2019 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 18, 2019 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 042
Research and development services in the field of pharmaceuticals; conducting clinical trials for others in the field of pharmaceuticals
First Use Anywhere: Aug 30, 2018
First Use in Commerce: Aug 30, 2018

Classification

International Classes
042